Biodexa Pharmaceuticals plc · NASDAQ:BDRX
Biodexa Pharmaceuticals — Investor Presentation (April 2026)
33 slides from Biodexa Pharmaceuticals's investor presentation, April 2026
Slide 1: Corporate Presentation
Corporate Presentation NASDAQ:BDRX April 2026
Slide 2: Disclaimer & cautionary language regarding forward-looking statements
Disclaimer & cautionary language regarding forward-looking statements The following presentation, including a hard copy of these slides/the talks given by the presenters, the information communicated during any delivery of the presentation and any question-and-answer only and and any document or mat
Slide 3: Highlights
Highlights • NASDAQ listed, <$5M market cap • Focused on rare GI oncology diseases • Funded Phase 3 program in FAP* • Phase 1 ready asset in GIST** • Semi-virtual organization • Near term milestones * Familial Adenomatous Polyposis ** GastroIntestinal Stromal Tumors 3
Slide 4: Company Strategy
Company Strategy BUILD DEVELOP PARTNER Build pipeline of assets Develop assets through License out to pharma focused on the GI / GI next stage/s of validation partners oncology space Progress through proof- Partners sponsor phase Target assets in late pre- of-concept 3 programme and clinical / early
Slide 5: Current pipeline
Current pipeline Grant Indication Preclinical Phase 1 Phase 2 Phase 3 Funding SPONSORED: Familial MTX230 eRapa (rapamycin) Adenomatous Orphan $20 million Polyposis (FAP) Gastrointestinal MTX240 Stromal Tumors Orphan (Molecular glue) (GIST) INVESTIGATOR INITIATED: Non-Muscle Invasive MTX230 eRapa Bla
Slide 6: MTX230
MTX230 eRapa (rapamycin) for treatment of Familial Adenomatous Polyposis (FAP) 6
Slide 7: Familial Adenomatous Polyposis (FAP)
Familial Adenomatous Polyposis (FAP) • Caused by single APC gene mutation, 70-75% hereditary • Manifests as proliferation (100s /1,000s) of polyps in the GI tract • If untreated, near 100% of patients develop colorectal cancer • Standard of care is active screening → polypectomy → colectomy and ileo
Slide 8: MTX230 – mechanism of action
MTX230 – mechanism of action • Wnt provides a signal to divide rather than differentiate • In APC mutation, Wnt signaling is constitutively active, meaning cells continue to proliferate (rather than differentiate) → clonal expansion and polyp formation • Wnt signaling cross-talks with mTOR → activat
Slide 9: eRapa vs Rapamune
eRapa vs Rapamune® • Rapamycin suffers from poor bioavailability and inter- patient PK variability 1500 • eRapa was formulated using a proprietary 0.3mg/kg eRapa nanoprecipitation process: 0.6mg/kg eRapa • enteric coated micro-particles dissolving pH>6.8 1.2mg/kg eRapa AUC (0-INF) • Solubility enhan
Slide 10: MTX230: Phase 2 in FAP
MTX230: Phase 2 in FAP Prevention of progression in FAP 12 month data Change from baseline (%) Cohort 2: 89% non-progression, 29% decrease in median polyp burden 10
Slide 11: Global eRapa Phase 3 study: Trial Design and Sites
Global eRapa Phase 3 study Trial Design and Sites TRIAL DESIGN GLOBAL REACH • Placebo-controlled, double- blind, registrational • n=168 • Inclusion: high risk pts with germline or phenotypic FAP diagnosis • Patient Stratification: • Intact colon vs post-surgery • Stage 3 / higher duodenal polyposis
Slide 12: Global eRapa Phase 3: Primary Endpoint and Timeline
Global eRapa Phase 3 Primary Endpoint and Timeline PRIMARY ENDPOINT: Progression-Free Survival (PFS) Composite Clinical Progression Measure Surgery /meets criteria Advancement of Diagnosis of high-grade Death by any cause for major surgery Spigelman Stage dysplasia or cancer Endpoints agreed in Type
Slide 13: MTX240
MTX240 Molecular glue for treatment of GastroIntestinal Stromal Tumors (GIST)
Slide 14: GastroIntestinal Stromal Tumors (GIST)
GastroIntestinal Stromal Tumors (GIST) • Tumors arise from Interstitial Cells of Cajal (ICCs) in GI wall, responsible for peristalsis [5] • ICCs normally express the tyrosine kinase KIT (CD117) → becomes constitutively activated in GIST [7] • GIST tumors occur in the stomach (~70%), small intestine
Slide 15: GIST – current and potential new therapies
GIST – current and potential new therapies • Surgical resection (when feasible) KIT WILD TYPE PDGFR COMPOUND PDGFR • Tyrosine Kinase Inhibitors (TKIs) Primary ATP-binding pocket Activation Loop D842V SDH insufficient BRAF NF1 exon 9 exon 11 exon 13 exon 14 exon 17 exon 18 V600E inhibit mutant KIT /
Slide 16: MTX240 – mechanism of action
MTX240 – mechanism of action [14] • Small molecule molecular glue developed to Phase I and tested in multiple PDX cancer models • MTX240 forces the stable complexation of PDE3a and SLFN12 (which must be co-expressed for lethality) • SLFN12 actively degrades tRNAs, preventing mRNA translation and pro
Slide 17: MTX240 - response in cancer types
MTX240 - response in cancer types • MTX240 efficacy demonstrated in 9/of 9 GIST cell lines • Certain other healthy cell types (eg MKs) express PDE3A, conferring on- target toxicity • Phase 1b/2a study will be designed to establish appropriate dose and regimen 17
Slide 18: MTX240 – proof of concept
MTX240 – proof of concept • Knock-in / knock-out studies confer sensitivity / resistance, respectively • PDX studies demonstrate efficacy in GISTs with different KIT mutations (p<0.01) [16]: 18
Slide 19: MTX240 – Phase 1b / 2a program
MTX240 – Phase 1b / 2a program Phase Dose escalation Expansion Subjects GIST patients GIST patients with demonstrated resistance to imatinib and sunitinib that express both SLFN12 and PDE3A Objectives Assess tolerability to find dose Assess tolerability and efficacy: and regimen - RECIST / tumor shr
Slide 20: Milestones / potential catalysts
Milestones / potential catalysts eRapa eRapa eRapa eRapa eRapa Early Access NMIBC Serenta Serenta Serenta Program Phase 2 data fully futility database initiated read out recruited analysis lock 1Q26 3Q26 4Q26 3Q27 1Q28 4Q28 4Q29 MTX240 MTX240 MTX240 MTX240 MTX240 MTX240 MTX240 License / Orphan Drug
Slide 21: Cap table (as of 04.07.26)
Cap table (as of 04.07.26) WAV ex. Ordinary shares ADSs % Price % Issued 373,056,808,922 746,113 100.0% 37.2% Pre-funded warrants 347 0.0% 0.0% Issued - in the money 746,460 100.0% 37.3% Warrants - Series L 1,219,512 $ 16.40 60.9% Warrants - Other 36,490 $ 366.07 1.8% Stock options 626 $ 3,073.00 0.
Slide 22: BDRX liquidity
BDRX liquidity Capitalization (£ in thousands) As of December 31, 2026 Actual Cash and cash equivalents 8,534 Long-term debt 0 Total equity 11,405 Total capitalization 11,405 Cash runway Q3 2026 22
Slide 23: Thank You
biodexa 0° ° e o® ° e eo \ 0°, ® ° ) e,0,° ° 0,9°o 9 eo - (eo) > m4 2 c 8 6 3 = e, FE 4 23
Slide 24: References
References 1. National Organisation for Rare Disorders 2. Orphanet 3. DataBridge Market Research. (2023). Gastrointestinal stromal tumor market size, trends and forecasts (2024-2032). Retrieved from https://www.databridgemarketresearch.com/reports/global-gastrointestinal-stromal- tumor-market 4. Fut
Slide 25: Additional Slides
ee ide a @ Qo @ i) biod exa oe pharinsenincals e @ e " 2 @ ° @ e [e080 ADDITIONAL SLIDES 0 e@@ @eo @e ., @ °e "9 ) 25
Slide 26: MTX230 – non-orphan indications / clinical studies
MTX230 – non-orphan indications / clinical studies PHASE 2 NMI BLADDER CANCER (ongoing) PHASE 1 PROSTATE CANCER (completed) • Placebo-controlled, two centers, (n=166,fully enrolled) • Open label dose escalation, single center, (n=14) • Inclusion: NMIBC diagnosis last 90 days, no prior BCG • Inclusio
Slide 27: ETV1 importance for efficacious glue
ETV1 importance for efficacious “glue” • The transcription factor ETV1 is expressed in ICCs – it is a lineage survival factor • ETV1 is unstable and normally rapidly degraded by the proteosome • Activated ERK (part of MAPK pathway) phosphorylates ETV1, thus preventing its Degradation degradation (vi
Slide 28: MTX228 tolimidone in Type 1 Diabetes
MTX228 tolimidone in Type 1 Diabetes The potential to restore β-Cell Function
Slide 29: MTX228 - summary
MTX228 - summary • Re-purposed Lyn kinase activator for Type 1 Diabetes • Extensive preclinical package developed by Pfizer • Preclinical data suggests Beta cell proliferation (University of Alberta Diabetes Institute) • Ongoing Phase 2 IIT at Alberta • IP (use) through XXXX • In-licensed from Melio
Slide 30: Type 1 Diabetes
Type 1 Diabetes • T1D is a complex interaction of genetics (esp HLA) and environmental triggers • Autoimmune attacks destroy insulin-producing beta cells in pancreatic islets • Lack of / reduced insulin → hyperglycemia → multiple co- morbidities • Other than exogenous insulin, limited therapeutic op
Slide 31: MTX228: mechanism of action
MTX228: mechanism of action • Signaling protein which modulates key intracellular functions such as: • Proliferation • Differentiation • Apoptosis • Migration, and • Metabolism • In fat cells it increases utilization of insulin and thus decreases blood sugar • In pancreatic islets: • activation of L
Slide 32: MTX228: preclinical data in T1D mouse models
MTX228: preclinical data in T1D mouse models • Tolimidone increases β-cell mass Improved glucose control in non-obese mouse model (NOS model) with preserved effect after • β-cell function preservation may treatment termination – protective effect of be due to a direct protective tolimidone activity
Slide 33: MTX228: clinical development plan
MTX230: clinical development plan Phase 2a (ongoing IIT at University of Alberta): • Efficacy dose confirmation study. Safety data complemented by earlier Pfizer/Melior studies • n ≈ 12-15 patients, 3 dose/escalations • Runs in parallel with preparations for Phase IIb Phase 2b (planned): • Aiming to
Biodexa Pharmaceuticals — Investor Presentation (April 2026) on 6ix